Whitehouse MW, Fletcher L, Crawford DH. Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. Am J Physiol Gastrointest Liver Physiol 300: G130 -G136, 2011. First published October 28, 2010 doi:10.1152/ajpgi.00162.2010.-It has been reported that the adjuvant-induced inflammation could affect drug metabolism in liver. Here we further investigated the effect of inflammation on drug transport in liver using taurocholate as a model drug. The hepatic disposition kinetics of [ 3 H]taurocholate in perfused normal and adjuvant-treated rat livers were investigated by the multiple indicator dilution technique and data were analyzed by a previously reported hepatobiliary taurocholate transport model. Real-time RT-PCR was also performed to determine the mRNA expression of liver bile salt transporters in normal and diseased livers. The uptake and biliary excretion of taurocholate were impaired in the adjuvant-treated rats as shown by decreased influx rate constant k in (0.65 Ϯ 0.09 vs. 2.12 Ϯ 0.30) and elimination rate constant k be (0.09 Ϯ 0.02 vs. 0.17 Ϯ 0.04) compared with control rat group, whereas the efflux rate constant k out was greatly increased (0.07 Ϯ 0.02 vs. 0.02 Ϯ 0.01). The changes of mRNA expression of liver bile salt transporters were found in adjuvant-treated rats. Hepatic taurocholate extraction ratio in adjuvant-treated rats (0.86 Ϯ 0.05, n ϭ 6) was significantly reduced compared with 0.93 Ϯ 0.05 (n ϭ 6) in normal rats. Hepatic extraction was well correlated with altered hepatic ATP content (r 2 ϭ 0.90). In conclusion, systemic inflammation greatly affects hepatic ATP content/production and associated transporter activities and causes an impairment of transporter-mediated solute trafficking and pharmacokinetics. hepatic extraction; bile salt transporter; systemic inflammation THE ADJUVANT-INDUCED INFLAMMATORY rat model has been used as an animal model for investigating the immunopathogenic mechanisms for chronic inflammatory synovitis (4). The development of systemic inflammation and changes in bone and cartilage in this model share common features with human rheumatoid arthritis or Reiter's syndrome (35). Besides local inflammatory response and distal joint destruction, a number of hepatic events have been recognized following adjuvant treatment and consequent cytokine activation. These include the defenestration of sinusoid, appearance of mitochondrial inclusions/tubularization, irregular-shaped lysosomes, increased level of ␣ 1 -acid glycoprotein (AAG, one of the acute phase proteins which increases in inflammatory diseases) (5) and iron concentration, and lower cytochrome P-450 level compared with normal rats (38). The hepatic metabolism and ion trapping of a xenobiotic (propranolol) in these rats was significantly impaired probably because of these changes (18).
hepatic extraction; bile salt transporter; systemic inflammation THE ADJUVANT-INDUCED INFLAMMATORY rat model has been used as an animal model for investigating the immunopathogenic mechanisms for chronic inflammatory synovitis (4) . The development of systemic inflammation and changes in bone and cartilage in this model share common features with human rheumatoid arthritis or Reiter's syndrome (35) . Besides local inflammatory response and distal joint destruction, a number of hepatic events have been recognized following adjuvant treatment and consequent cytokine activation. These include the defenestration of sinusoid, appearance of mitochondrial inclusions/tubularization, irregular-shaped lysosomes, increased level of ␣ 1 -acid glycoprotein (AAG, one of the acute phase proteins which increases in inflammatory diseases) (5) and iron concentration, and lower cytochrome P-450 level compared with normal rats (38) . The hepatic metabolism and ion trapping of a xenobiotic (propranolol) in these rats was significantly impaired probably because of these changes (18) .
In addition to hepatic drug metabolism, bile excretion is another important pathway for drug elimination, which involves in active transport mechanisms by various hepatobiliary transporters. Recently, studies have focused on regulation of these transporters at the level of gene expression during inflammation, cholestasis, and liver regeneration (6, 9, 11, 12) . However, little has been reported about the effects of systemic inflammation on the activity of the transporters.
In this study, we examine the effects of systemic inflammation on the hepatic pharmacokinetics of solutes depending on active transport mechanisms, as distinct from our previous emphasis on metabolism (18) . Taurocholate, an endogenous solute that is mainly dependent on Na ϩ -taurocholate cotransporting polypeptide (Ntcp, Slc10a1) and organic anion transporting polypeptide (Oatp, Slc21a) uptake into the hepatocyte and on biliary excretion by the bile salt export pump (Bsep, Abcb11), was used as the model compound for this purpose (19, 25, 37) . A physiologically based, hepatobiliary transport model was used in this work for data analysis. The resulting pharmacokinetic parameters were then related to observed changes in liver physiology induced by the systemic inflammation. We found that the hepatic extraction ratio of taurocholate was well correlated to ATP levels in the liver.
MATERIALS AND METHODS
Chemicals. All chemicals were purchased from Sigma Chemical (Castle Hill, New South Wales, Australia). [ 3 H]taurocholate was supplied by New England Nuclear (Boston, MA).
Animals and treatment. Animal studies were carried out according to protocols approved by the University of Queensland Animal Ethics Committee. Animals were treated as previously reported (18) . One group of female dark Agouti rats (150 Ϯ 10 g) were given 0.5 mg of heat-killed and delipidated Mycobacterium tuberculosis (mixed human strains, Ministry of Agriculture, Weybridge, UK) dispersed in 0.1 ml of squalane by a single subcutaneous injection into the tail base to elicit adjuvant-induced polyarthritis (27, 38) . The other group of normal control rats was treated with vehicle alone. Animals were euthanized after 15 days, when the polyarthritis was fully expressed.
Serum biochemistry measurement. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) levels were assessed and reported previously (18) .
In situ rat liver perfusions. The in situ perfused rat liver preparation was prepared as follows and has been described in detail elsewhere (7) . Briefly, normal and adjuvant-induced systemic inflammatory rats were anesthetized by an intraperitoneal injection of xylazine 10 mg/kg and ketamine-hydrochloride 80 mg/kg. Following laparotomy, rats were heparinized (heparin sodium, 200 units) via the inferior vena cava. The bile duct was cannulated with PE-10 tubing (Clay Adams).
The portal vein was then cannulated by an intravenous catheter and the liver perfused via this cannula with 25 mM MOPS-buffered Ringer solution (pH 7.4) containing 2% bovine serum albumin and 15% (vol/vol) prewashed canine red blood cells (obtained from School of Veterinary Sciences, The University of Queensland, Brisbane, Australia) and was oxygenated via a Silastic tubing lung ventilated with oxygen. The perfusion system was nonrecirculating and employed a peristaltic pump. Animals were euthanized by thoracotomy after perfusion initiation and the thoracic inferior vena cava was cannulated with PE-240 tubing. Oxygen consumption, bile flow, perfusion pressure, and macroscopic appearance were used to assess liver viability.
After a 10-min stabilization period, aliquots (50 l) of perfusate containing [ 3 H]taurocholate (3 ϫ 10 6 dpm) and Evans blue dyelabeled albumin (3 mg/ml) were administered to the liver through the portal vein cannula and outlet samples were collected (1 s ϫ 20, 4 s ϫ 5, 10 s ϫ 5, 30 s ϫ 5) via a fraction collector for 4 min.
Collected samples were centrifuged, and aliquots (100 l) of the clear supernatant were taken for scintillation counting as measurement [ 3 H]taurocholate of using a MINAXI beta TRI-CARB 4000 series liquid scintillation counter (Packard Instruments). Aliquots of 100 l were also removed from the outflow samples for absorption spectrophotometric measurement of the Evans Blue dye at 620 nm by using a Spectracount plate counter (Packard).
Histopathological analyses. Normal and adjuvant-treated rat liver samples were prepared as previously described for transmission electron microscopy and scanning electron microscopy (18) .
Biochemical analyses of hepatic components. Intrahepatic AAG levels; hepatic microsomal protein, cytoskeleton residue, and cytochrome P-450 levels; and hepatic iron concentrations of normal and adjuvanttreated rat liver were determined as described previously (18) .
Determination of hepatic Gst level. Glutathione S-transferase (Gst) tissue levels were assayed according to Alin et al. (2) . The method was based on the reaction between 1-chloro-2,4-dinitrobenzene (CDNB) and glutathione in a sodium phosphate buffer reaction system (pH 6.5, 30°C). Activity was measured spectrometrically at 340 nm (⑀ ϭ 9,600 M Ϫ1 ·cm Ϫ1 ). Briefly, 1 ml of total reaction mixture contained 1 mM CDNB dissolved in 100% ethanol, 1 mM glutathione, and 50 l of liver tissue homogenate in assay buffer. The reaction rate for all enzyme activity assays (mol·min Ϫ1 ·mg Ϫ1 protein) was determined by subtracting the background activity rate. Cellular protein content was estimated by Lowry method (23) .
Determination of hepatic ATP concentration. ATP content was assayed according to Evdokimova et al. (8) . Briefly, liver slices were washed twice in saline and sonicated instantly in 1 ml of 2% perchloric acid. The intracellular ATP content was measured in neutralized perchloric acid extracts using the ATP Bioluminescense Assay Kit CLS II (Boehringer-Mannheim, Mannheim, Germany). The results were expressed as nanomoles ATP per milligram protein.
Determination of mRNA expression for bile salt transporters. Liver tissue was snap frozen and stored at Ϫ70°C before RNA extraction. RNA was extracted from 100 -150 mg liver tissue using TRIzol Reagent (Invitrogen, Mt Waverley, Victoria, Australia) as per manufacturer's instructions. Following RNA extraction, DNA contaminations were removed by incubation with RNase-free DNase-1. Firststrand cDNA was synthesized from 1 g total RNA using SuperScript III reverse transcriptase (Invitrogen) and oligo(dT)15 as per manufacturer's instructions. Real-time RT-PCR was then performed to quantitate the gene expression of bile transporters and the housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPD) for each sample. An ABI Prism 7700 sequence detection system (Applied Biosystems, Scoresby, Victoria, Australia) was used for real-time RT-PCR experiments. Reactions were performed in a 25 l volume with 400 nM forward primer, 400 nM reverse primer and 12.5 ng of cDNA. Nucleotides, MgCl2, Taq polymerase, and SYBR green were included in the QuantiTect SYBR Green PCR master mix (Qiagen, Clifton Hill, New South Wales, Australia). The PCR conditions included a denaturation step at 94°C for 15 min. Amplification was carried out for 40 cycles (denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s). Quantification was performed by using the standard curve method for relative quantification of gene expression (Applied Biosystems, Scoresby, Victoria, Australia). Primer sequences used for analysis of GAPD, Ntcp (Slc10a1), Bsep (Abcb11), Oatp1a1 (Slc21a1), Oatp1a4 (Slc21a5), Oatp1b2 (Slc21a10), and multidrug resistance-associated protein 3 (Mrp3, Abcc3) were as follows: GAPD forward TCC TGC ACC ACC AAC TGC TTA GC; GAPD reverse GCC TGC TTC ACC ACC TTC TTG ATG; Ntcp forward CAA GTC CAA AAG GCC ACA C; Ntcp reverse GCC CAC ATT GAT GAC AGA GA; Bsep forward GGG CAG TCC ACC CAT CTA C; Bsep reverse AGC CCA GGA TGA CAA AGA AC; Oatp1 forward TCT GCC TGC CTT CTT CAT TC; Oatp1a1 reverse GTG TGC TCG CTT TCC TTC TC; Oatp2 forward TGC GGA GAT GAA GCT TAC C; Oatp1a4 reverse TCC TCC GTC ACT TTC GAC CTT; Oatp1b2 forward ATA TGT AGA CCT GAG AAG TG; Oatp1b2 reverse ATG CTT CTC AGA GAC CAT AG; Mrp3 forward TCC CAC TTC TCG GAG ACA GTA ACT; Mrp3 reverse CAC CTT AGC ATC ACT GAG GAC CTT. Primers were designed by use of Primer 3 software (Whitehead Institute for Biomedical Research, Cambridge, MA). Results for each sample are calculated as a ratio of the GAPD concentration.
[ 3 H]taurocholate recovery in bile. Bile was collected continuously for entire 20-min period after bolus injection by using PE-10 tubing and was quantified by weight. Aliquots (100 l) of bile were taken for scintillation counting. The ratio of [ 3 H]taurocholate recovery in bile (Fbile) was determined from the following equation:
F bile ϭ total radioactivity recoved from bile ⁄ total radioactivity injected to liver Data analysis. A mixture of two inverse Gaussian density functions with correction for catheter effects was used to describe the outflow concentration-time profiles of Evans Blue dye-labeled albumin. A detailed description of the mathematical theory and modeling methods has been given previously (15, 16) . Kinetic parameters of [ 3 H]taurocholate were derived from a physiologically based, hepatobiliary taurocholate transport model that accounts for vascular dispersion, described in detail elsewhere (17) . A schematic representation of hepatobiliary taurocholate transport is illustrated in Fig. 1 . The equations for describing the pharmacokinetics of taurocholate fy(s) in the cell and the Laplace domain function (transit time density function) f(s) for taurocholate extraction across the liver are as follows:
where s is the Laplace variable, fP(s) is the transit time density of nonpermeating reference molecule (Evans Blue dye-labeled albumin used in this study), and f(s) is the Laplace domain function (transit time density function) for taurocholate extraction across the liver. Nonparametric estimates of hepatic availability (F), mean transit time (MTT), and normalized variance (CV 2 ) were determined from the outflow concentration (C) vs. time (t) profiles for the reference from Eqs. 3-6 by using the parabolas-through-the-origin method (extrapolated to infinity) as previously described (28) . In brief,
where AUC ϭ ͐ 0 ϱ C(t)dt is the area under the solute concentration vs. time curve, Q is the perfusate flow rate, and D is the dose of solute administered. All concentrations used were expressed in molar equivalents. Hepatic extraction ratio (E) equals to 1 Ϫ F.
where AUMC ϭ ͐ 0 ϱ tC(t)dt is the area under the first moment curve.
Statistical analysis. All data are presented as means Ϯ SD unless otherwise stated. Statistical analysis was performed by Student's t-test and regression analysis where appropriate. Statistical significance was taken at the level P Ͻ 0.05.
RESULTS
Liver physiology and biochemistry. The experimental parameters of the perfusion studies (perfusion rate, perfusion pressure, bile flow, oxygen consumption) were comparable to those reported previously (15) (16) (17) , indicating the success of experiments. The adjuvant-treated rats displayed marked alterations in liver histology with inclusions and cristae tubulization of mitochondria, irregularly shaped lysosomes, and a marked decrease in size of endothelial fenestrae. The adjuvant-treated rats also had significantly elevated serum biochemistry markers such as AST, ALT, and ALP. The adjuvant-treated group had significantly higher AAG content (P Ͻ 0.05) and iron levels (P Ͻ 0.001), but significantly lower levels of cytochrome P-450 (P Ͻ 0.05). These results have been reported in the previous publication (18) . In addition, ATP and Gst level in the livers from adjuvant-treat animals were significantly lower (P Ͻ 0.01) than those levels in control group as shown in Table 1 .
mRNA expression of liver bile salt transporters. Because hepatobiliary transport of taurocholate mainly involves in active transport mechanisms, we investigated the mRNA level of major transporters (Ntcp, Oatp1a1, Oatp1a4, Oatp1b2, Mrp3, Bsep) in normal and adjuvant-treated rat liver by the RT-PCR method. Compared with the normal group, mRNA expression of Oatp1a1, Oatp1a4 and Bsep decreased ϳ38, 61, and 36%, respectively in adjuvant-treated group as shown in Fig. 2 . In contrast, mRNA expression level of efflux transporter Mrp3 was found to increase ϳ73% in the disease group compared with the normal group. Although there was ϳ13 and 7% decrease in Ntcp and Oatp1b2 mRNA expression level in adjuvant-treated rats, the changes did not reach statistical significance.
Hepatic extraction ratio and biliary recovery ratio. Table 2 shows a comparison of nonparametric moments and [
3 H]taurocholate biliary recovery ratio between normal and adjuvanttreated rats. The treated group showed significantly decreased hepatic extraction ratio (P Ͻ 0.05) and [ 3 H]taurocholate biliary recovery ratio. As shown in Fig. 3 , the extraction ratio was significantly correlated with ATP levels in the liver (P Ͻ 0.001). The MTT was significantly increased in the treatment group. No significant difference in CV 2 values was found between treated animals and controls.
Modeling and data fitting of outflow concentration fractiontime profiles. Figure 4 shows a comparison of typical measured and predicted (fitted data) outflow concentration fraction-time profiles for taurocholate in the isolated perfused normal and adjuvant-treated rat liver. Co-administered Evan blue dyelabeled albumin and [
3 H]water were used for estimation of sinusoidal and cellular volumes. Data were well fitted by a physiologically based hepatobiliary taurocholate transport (Fig. 1) . It is evident that adjuvant treatment increased the peak taurocholate outflow concentration and decreased the decline of tail section in outflow concentration (higher MTT). Figure 4 also demonstrates that the area under the curve for adjuvant-treated animals is significantly larger (lower E) than in the normal animals. Table 3 compares the kinetic parameters derived from the hepatobiliary taurocholate transport model fitting for taurocholate between normal and adjuvant-treated animals. Adjuvant-treated animals showed significantly smaller k in (P Ͻ 0.001) and k be (P Ͻ 0.01) values compared with normal animals, whereas adjuvant-treated animals had a significantly larger k out value (P Ͻ 0.001). As shown in Fig. 3 , k be correlated better to liver ATP level compared with k in and k out .
DISCUSSION
In this paper we set out to understand the effect of systemic inflammation on the uptake of taurocholate in hepatocytes and how this process was controlled by hepatic transporters. This information is important because the inflamed liver is a common feature in the early stage of many liver diseases and therefore it would be useful to understand how endogenous solutes behave in the diseased liver, as opposed to the healthy liver where most studies have been conducted.
In general, hepatic extraction of solute is affected by perfusate flow, hepatic metabolism (intrinsic clearance), permeability surface area product (sinusoid space), and efflux from hepatocyte to perfusate (32) . We set out to mathematically model the process. Given that the bulk of taurocholate synthesized in liver is excreted into the bile canaliculus in an unchanged form (1), further taurocholate metabolism was excluded in our pharmacokinetic calculations. It was well documented that taurocholate transport in the liver involves influx from sinusoid across the cytoplasmic membrane via Ntcp or Oatps, efflux from the hepatocytes into sinusoid via Mrp3, and excretion from the hepatocytes into the bile via the canalicular membrane (mediated with Bsep) (25) . Using the multiple indicator dilution (MID) technique in perfused rat livers, we characterized these steps by their pharmacokinetic parameters: influx rate constant k in , efflux rate constant k out , and elimination rate constant k be . Data fitting from the MID study showed that k in and k be was significantly decreased in adjuvant-treated inflamed rat livers whereas k out was significantly increased instead. In addition, the biliary recovery of taurocholate dropped ϳ25% in the adjuvant-treated group.
Stepwise regression analysis showed that the hepatic ATP level was a good predictor of E. The decreased E of taurocholate is a product of a decreased k in , k be , permeability surface area product, and an increased k out . As shown in Fig. 4 , a linear relationship existed between E values and hepatic ATP content in normal and adjuvant-treated rats and hepatic ATP levels were reduced in adjuvant-treated rats. Although the basolateral uptake of taurocholate is not primarily dependent on ATP, transporter-mediated (Mrp3) efflux of taurocholate from hepatocyte to sinusoid and Bsep-mediated biliary excretion of taurocholate are both ATP-dependent transport processes. Consistent with reduced liver ATP level, the pharmacokinetic parameter describing the biliary excretion k be was also decreased in adjuvant-treated rats. However, k out was about threefold increased in these rats, which was contradictory to the reduced ATP level. The linear relationship found between E values and hepatic ATP content may also suggest that k be is a more important factor to determine E compared with k in and k out . Indeed, as shown in Fig. 3 , the correlation between k be and liver ATP content was much better than that between k in or k out and ATP content. A poor correlation between k in and hepatic ATP levels was consistent with basolateral uptake for taurocholate (k in ) being ATP independent. Taken together, these data suggest that the reduced activity of hepatic transporters responsible for each step after adjuvant treatment may have an association with lower level of ATP, although its mechanism is not yet defined.
As shown in Fig. 4 , adjuvant treatment affected taurocholate outflow fraction-time profiles: outflow profiles for the adjuvant-treated group have a larger AUC and longer tail segment compared with the control group. This is consistent with the smaller hepatic extraction ratio and larger hepatic retention (MTT) of taurocholate in diseased liver. In this study, Evans blue dye-labeled albumin was used as a surrogate marker to measure liver sinusoidal volume. The sinusoidal volume in diseased livers was found to be significantly larger than that in normal livers (P Ͻ 0.05). In addition, there was a slow efflux of taurocholate for diseased livers, consistent with outflow profiles seen for blood retained in parts of the liver such as the interconnecting vessels relative to large and branch vessels (29) . In this case, the retention of blood probably reflects the reported decreased perfusion in certain microvascular segments after endotoxin insult, probably partly due to adhering leukocytes impairing flow (14, 24, 34) . The increased retention of taurocholate in adjuvant-treated animals is also partly due to a reduction in biliary excretion (k be ). The larger liver weight observed in adjuvant-treated rats would also account for an increase in MTT.
We also measured mRNA expression of hepatic transporters. The expression of transporters responsible for taurocholate uptake and bile excretion (e.g., Oatp1a1, Oatp1a4, and Bsep) was downregulated in adjuvant-treated rats, whereas the expression of Mrp3 (mainly mediates efflux of taurocholate from hepatocytes to sinusoid) was upregulated nearly twofold in inflamed rat livers. Our results are consistent with previous report that inflammation decreased expression of hepatobiliary transporters at the basolateral or canalicular membrane (9) . Inflammatory cytokines including TNF-␣, IL-1␤, and IL-6, secreted by macrophages, and Kupffer cells have been characterized as mediators that reduce bile flow and organic anion excretion (30, 39) . TNF-␣-mediated upregulation of Mrp3 has been reported before in rat (3) . Recent studies in human hepatocytes also showed that both TNF-␣ and IL-6 upregulated expression of the sinusoidal MRP3 efflux pump at the protein level (21) . Previously, the effects of inflammation on the expression and/or functionality of other transporters in the liver, such as P-glycoprotein, were also intensively investigated. The results showed that, after induction of inflammation, mRNA expression of mdr1a was constantly reduced (10, 26, 33) , except in one study where it was not modified (36) . Contradictory results were observed for mdr1b with either an increase (10, 36) or a deduction in mRNA expression (26) . The functionality of P-glycoprotein was found to be depressed in inflammation (10, 26) . Since P-glycoprotein does not play an important role in the transport of taurocholate in liver, its expression and functionality was not examined in our study. Downregulation of some other proteins such as calcium channels and ␤-adrenergic target proteins has been reported in inflammation (20, 22, 31) . Different from the changes of hepatic transporters in inflammatory condition, these changes would not affect drug pharmacokinetics in vivo but lead to alteration of drug pharmacodynamics instead. Reduced response to propranolol was reported in adjuvant arthritis rats although increased plasma concentration was observed (13), which was attributed to altered ␤-adrenergic receptors function.
In the inflamed liver we would therefore predict reduced uptake and increased efflux of taurocholate, thus reducing the concentration of the molecule inside hepatocytes. This could be due to reduced ATP and therefore reduced activity of ATP-dependent transporters, coupled to lower transporter expression levels due to the downregulating effect of proinflammatory cytokines. In vivo, the reduced transporter activity might result in higher drug plasma concentration, and, therefore, altered drug response.
In conclusion, administration of adjuvant to rats and the ensuing systemic inflammation impacted on hepatic architecture, biochemistry, and solute disposition by a combination of transporter expression changes on the mRNA level and decrease in hepatic ATP content. It was shown that the hepatic extraction of taurocholate was significantly impaired, consistent with a decreased uptake of taurocholate and a reduction in biliary excretion. The changes in hepatic extraction ratio in inflamed animals might be the result of an impaired ATPdependent canalicular transport process and an increase in basolateral efflux transporter expression. The hepatic ATP levels were found to be a good predictor for hepatic extraction ratio of taurocholate. The reduced ATP level in diseased rat livers may also reflect other changes that have affected hepatic extraction.
